LAG3 and ovarian carcinoma: showed that in a murine model of ovarian cancer, single-agent treatments with anti-PD-1 or anti-LAG-3 antibodies led to compensatory upregulation of other checkpoint molecules such as LAG-3 and CTLA-4, ultimately reducing therapeutic efficacy.